Seve, we are very undervalued based on the DCF analysis Sarissa uses to enter and maintain positions. The value is not the cashflow a small one drug company can generate... the value is in what Big Pharma can generate pushing it through its channels. That being said, I would sign off on a $4 buyout today.
Market Data 
Markets 
AI
